BACKGROUND Fascioliasis and paragonimiasis are widespread foodborne trematode diseases, affecting millions of people in more than 75 countries. The treatment of choice for these parasitic diseases is based on triclabendazole, a benzimidazole derivative which has been suggested as a promising drug to treat pregnant women and children. However, at the moment, this drug is not approved for human u...

Triclabendazole is reported to be highly effective in treatment of human fascioliasis. We present 7 of 19 selected cases of human fascioliasis referred to our center in the Cusco region of Peru that failed to respond to triclabendazole. These were mostly symptomatic adults of both sexes that continued passing Fasciola eggs in the stool despite multiple treatments with 2 doses of triclabendazole...

Human fascioliasis caused by Fasciola hepatica or Fasciola gigantica is an increasing global problem. The mainstay of current treatment is triclabendazole, but resistance in animals has been described, and it is not available in many countries. The antimalarial artesunate has an excellent safety profile, and there is increasing evidence of its efficacy against other parasites both in vitro and ...

BACKGROUND Fascioliasis is an emerging zoonotic disease of considerable veterinary and public health importance. Triclabendazole is the only available drug for treatment. Laboratory studies have documented promising fasciocidal properties of the artemisinins (e.g., artemether). METHODOLOGY We carried out two exploratory phase-2 trials to assess the efficacy and safety of oral artemether admin...

Various anthelmintics belonging to the pharmacolog~cal group of benzimidazoles (oxibendazole, thiabendazole, albendazole, oxfendazole, flubendazole, mebendazole, parbendazole, fenbendazole and triclabendazole) were tested and compared for their In vitro and in vivo activity against an infection of rainbow trout Onchorhynchus myhss by Gyrodactylus. The trout were also observed for signs of toxic...

BACKGROUND The Bolivian northern Altiplano is characterized by a high prevalence of Fasciola hepatica infection. In order to assess the feasibility, safety and efficacy of large-scale administration of triclabendazole as an appropriate public health measure to control morbidity associated with fascioliasis, a pilot intervention was implemented in 2008. MATERIALS AND METHODS Schoolchildren fro...

The Ras-adenylyl cyclase-protein kinase A nutrient-sensing pathway controls metabolism, proliferation and resistance to stress in Saccharomyces cerevisiae. The genetic disruption of this pathway increases resistance to a variety of stresses. We show here that the pharmacological inhibition of this pathway by the drug triclabendazole increases resistance to oxidants, heat stress and extends the ...

RESISTANCE to triclabendazole in field isolates of the liver fluke Fasciola hepatica in sheep was described for the first time by Overend and Bowen (1995) in Australia. In Europe, resistance of F hepatica in sheep to triclabendazole has been reported in Ireland (Lane 1998), Scotland (Mitchell and others 1998), Wales (Thomas and others 2000) and the Netherlands (Moll and others 2000). On the Dut...

Here we report a rare case of living Fasciola hepatica in biliary tract. The patient was in acute phase of infection and treated successfully with 10 mg/kg oral triclabendazole after the fluke was extracted using endoscopic retrograde cholangiopancreatography (ERCP).